Abstract
Accumulating evidence suggests that elevated plasma triglycerides concentrations, in both the fasting and the postprandial states, may pose a significant independent risk for cardiovascular disease (CVD). Both fasting and postprandial lipoprotein concentrations vary substantially among individuals, and this interindividual variability is driven by a combination of non-genetic and genetic factors. Regarding the genetic component, the efforts to elucidate the variability in postprandial response have resulted in the identification of associations with multiple lipid candidate genes. However, most reported associations are based on very simple models including one single-nucleotide polymorphism (SNP) or haplotype at a time and small sample sizes. Progress in this promising area of research requires more comprehensive experimental models, including larger sample sizes that will allow investigating gene-gene interactions. Reviews of the literature in the area of ApoA5, GCKR, and PLIN genes and postprandial lipemia are used to demonstrate the complexities of genotype-phenotype associations. Knowledge of how these and other genes influence postprandial response should increase the understanding of personalised nutrition.
Keywords: Gene-diet interaction, nutrigenetics, polymorphism, postprandial lipemia, triglycerides, GCKR gene, cardiovascular disease, ApoA5 gene, PLIN gene, single-nucleotide polymorphism
Current Vascular Pharmacology
Title: Nutrigenetics of the Postprandial Lipoprotein Metabolism: Evidences From Human Intervention Studies
Volume: 9 Issue: 3
Author(s): Pablo Perez-Martinez, Antonio Garcia-Rios, Javier Delgado-Lista, Francisco Perez-Jimenez and Jose Lopez-Miranda
Affiliation:
Keywords: Gene-diet interaction, nutrigenetics, polymorphism, postprandial lipemia, triglycerides, GCKR gene, cardiovascular disease, ApoA5 gene, PLIN gene, single-nucleotide polymorphism
Abstract: Accumulating evidence suggests that elevated plasma triglycerides concentrations, in both the fasting and the postprandial states, may pose a significant independent risk for cardiovascular disease (CVD). Both fasting and postprandial lipoprotein concentrations vary substantially among individuals, and this interindividual variability is driven by a combination of non-genetic and genetic factors. Regarding the genetic component, the efforts to elucidate the variability in postprandial response have resulted in the identification of associations with multiple lipid candidate genes. However, most reported associations are based on very simple models including one single-nucleotide polymorphism (SNP) or haplotype at a time and small sample sizes. Progress in this promising area of research requires more comprehensive experimental models, including larger sample sizes that will allow investigating gene-gene interactions. Reviews of the literature in the area of ApoA5, GCKR, and PLIN genes and postprandial lipemia are used to demonstrate the complexities of genotype-phenotype associations. Knowledge of how these and other genes influence postprandial response should increase the understanding of personalised nutrition.
Export Options
About this article
Cite this article as:
Perez-Martinez Pablo, Garcia-Rios Antonio, Delgado-Lista Javier, Perez-Jimenez Francisco and Lopez-Miranda Jose, Nutrigenetics of the Postprandial Lipoprotein Metabolism: Evidences From Human Intervention Studies, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495495
DOI https://dx.doi.org/10.2174/157016111795495495 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Current Pharmaceutical Design Management of Osteoporosis: Seeing the Future
Medicinal Chemistry Reviews - Online (Discontinued) Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Editorial (Thematic Issue: Medication Management for People with Dementia or Cognitive Impairment)
Current Clinical Pharmacology Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews Systemic Vasculitis: An Epidemiological Perspective
Current Immunology Reviews (Discontinued) Asymmetric Dimethylarginine: A Possible Link between Vascular Disease and Dementia
Current Alzheimer Research The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Editorial [Hot Topic: The Medicinal Chemistry of New Agents to Treat Obesity (Guest Editor: Jinhwa Lee)]
Current Topics in Medicinal Chemistry Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Ex Vivo and In Vivo Approaches to Study Mechanisms of Cardioprotection Targeting Ischemia/Reperfusion (I/R) Injury: Useful Techniques for Cardiovascular Drug Discovery
Current Drug Discovery Technologies Analysis of Contrast-Enhanced Intravascular Ultrasound Images for the Assessment of Coronary Plaque Neoangiogenesis: Another Step Closer to the Identification of the Vulnerable Plaque
Current Pharmaceutical Design Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews New Strategies and Biological Agents in the Treatment of Autoimmune Inflammatory Diseases. Progress and Challenges
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations
Recent Advances in Drug Delivery and Formulation Treatment of Chronic Myeloid Leukemia Elderly Patients in the Tyrosine Kinase Inhibitor Era
Current Cancer Drug Targets Cerebral Amyloid Angiopathy-related Intracerebral Hemorrhage Score For Predicting Outcome
Current Neurovascular Research A Review on the Risk of Myocardial Infarction Associated with the NSAID Diclofenac
Cardiovascular & Hematological Disorders-Drug Targets Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry